Physician profile
Robert W Weber
NPI 1265505291
$338,265.41
in general payments reported to CMS, 2019-2025
76 companies · $105K in 2025
The $105K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $15K · 2021: $5,068 · 2022: $62K · 2023: $64K · 2024: $39K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $145K · Travel and Lodging: $27K · Consulting Fee: $18K · Food and Beverage: $17K · Education: $882 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $144,743.00 |
| Travel and Lodging | $27,161.93 |
| Consulting Fee | $18,031.50 |
| Food and Beverage | $17,110.57 |
| Education | $882.40 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $121,727.71 | 2021-2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $69,459.54 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $37,222.04 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Amgen INC. | $33,320.13 | 2019-2024 | Lumakras, Nplate, Vectibix |
| Genentech USA, INC. | $10,753.67 | 2019-2024 | Phesgo, Lunsumio, Gazyva |
| Genzyme Corporation | $7,938.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $7,445.75 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $6,951.41 | 2019-2025 | Venclexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,724.69 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $3,915.94 | 2025 | |
| Incyte Corporation | $3,873.09 | 2019-2025 | Monjuvi, Jakafi, Niktimvo |
| Novartis Pharmaceuticals Corporation | $3,730.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,715.84 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Celgene Corporation | $3,444.54 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Kite Pharma, INC. | $3,104.07 | 2020-2023 |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,994.23 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Exelixis INC. | $2,126.35 | 2020-2024 | Cabometyx |
| Pfizer INC. | $1,222.54 | 2019-2025 | |
| Puma Biotechnology, INC. | $1,163.20 | 2019 | |
| Astellas Pharma US INC | $961.25 | 2019-2025 | Xtandi, Padcev, Xospata |
| Lilly USA, LLC | $916.59 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $797.90 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Seagen INC. | $664.24 | 2020-2025 | Padcev, Adcetris, Tivdak |
| Modernatx, INC. | $600.00 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $462.86 | 2019-2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $366.97 | 2019-2025 | Fruzaqla, Alunbrig, Advate |
| Coherus Oncology, INC. | $354.87 | 2023-2025 | Loqtorzi |
| Rigel Pharmaceuticals, INC. | $330.25 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Epizyme, INC. | $314.24 | 2020-2022 | |
| Eisai INC. | $292.40 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $279.99 | 2019-2025 | |
| Sobi, INC | $229.39 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $224.39 | 2021-2024 | Xarelto, Invega Sustenna, Invega |
| Aveo Pharmaceuticals, INC. | $180.08 | 2021-2023 | Fotivda |
| Taiho Oncology, INC. | $170.31 | 2019-2025 | |
| Array Biopharma INC | $166.35 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $133.11 | 2019-2021 | |
| Clovis Oncology, INC. | $130.18 | 2019-2022 | |
| Octapharma USA, INC. | $128.88 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Viiv Healthcare Company | $118.44 | 2022-2025 | Cabenuva, Apretude |
| Dova Pharmaceuticals | $118.14 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $102.71 | 2023-2024 | Orgovyx |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Agios Pharmaceuticals, INC. | $93.31 | 2019-2025 | Pyrukynd |
| Invivyd INC | $82.29 | 2024-2025 | Pemgarda |
| Foundation Medicine, INC. | $79.11 | 2020-2023 | |
| Cti Biopharma Corp. | $77.66 | 2023 | Vonjo |
| Stemline Therapeutics INC. | $64.00 | 2024-2025 | Orserdu |
| Myovant Sciences INC. | $61.91 | 2021-2022 | |
| Lundbeck LLC | $60.63 | 2023-2024 | Vyepti |
| Beigene USA, INC. | $58.86 | 2020-2023 | Brukinsa |
| Genmab U.S., INC. | $51.30 | 2023 | Epkinly |
| Blueprint Medicines Corporation | $50.64 | 2020-2022 | |
| Grifols USA, LLC | $49.71 | 2022-2023 | Gamunex-C |
| Tersera Therapeutics LLC | $45.69 | 2021 | |
| Gilead Sciences, INC. | $44.56 | 2021-2022 | |
| Pharmaessentia USA Corporation | $37.55 | 2023 | Besremi |
| Novocure INC. | $36.99 | 2025 | Optune Lua (Novottf-200t) |
| Mirati Therapeutics, INC. | $36.27 | 2024 | Krazati |
| Sirtex Medical INC | $34.07 | 2019-2020 | |
| Geron Corporation | $33.37 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $31.63 | 2024 | Qinlock |
| Tesaro, INC. | $27.63 | 2019 | |
| Teleflex LLC | $27.33 | 2023 | Arrow |
| Servier Pharmaceuticals LLC | $23.65 | 2024 | |
| Genentech, INC. | $21.99 | 2020 | |
| Secura Bio, INC. | $21.67 | 2023 | Copiktra |
| Acceleron Pharma, INC. | $21.43 | 2021 | |
| Emd Serono, INC. | $20.72 | 2021 | |
| Ge Healthcare | $19.47 | 2022 | |
| Iovance Biotherapeutics, INC. | $17.76 | 2025 | Amtagvi |
| Acrotech Biopharma INC. | $16.68 | 2025 | Beleodaq |
| Karyopharm Therapeutics INC. | $15.53 | 2022 | |
| Legend Biotech USA INC. | $13.99 | 2025 | Carvykti |
| Eusa Pharma (US) LLC | $11.79 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,180.60 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.